Bharat Biotech Reduces Price of MOSQIVAC Malaria Vaccine by Nearly 40%

Exam-focused facts from the 25 October 2026 current affairs briefing.

Key facts

Bharat Biotech announced a nearly 40% reduction in the price of MOSQIVAC, the RTS,S/AS01 malaria vaccine, under an agreement executed by UNICEF and financially backed by Gavi.
The Hyderabad-based company said the price cut will help protect another 1 million children and generate USD 50 million in savings.
Developed by GSK, RTS,S/AS01 is the world's first malaria vaccine, now manufactured by Bharat Biotech under the brand name MOSQIVAC.
The company highlighted the urgency of the move, noting one child dies from malaria every minute.